Technology

Abstracts & Publications

Abstracts & Publications



2017 American Society of Clinical Oncology, Chicago, IL :

  • KRAS and P-STAT3 Inhibition by SBT-100 Synergizes with Gemcitabine and Inhibits Pancreatic Cancer Growth In Vivo.

  • Single Domain Antibody (SBT-100) Crosses the Blood Brain Barrier (BBB) and Inhibits Human Glioblastoma by Selectively Targeting KRAS and P-STAT3.


2017 American Association for Cancer Research, Washington D.C. :

  • Single Domain Antibody (sdAb) Localizes In Cancer Cells to Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Resulting in Therapeutic Inhibition of Multiple Cancers.


2016 San Antonio Breast Cancer Symposium, San Antonio, TX :

  • Single Domain Antibody (SBT-100) Inhibits Growth of Human HER2+ and Triple Negative Breast Cancers (TNBC) in Xenografts by Binding STAT3 and P-STAT3.


2016 University of South Florida’s Annual Ophthalmology Symposium, Tampa, FL :

  • Single Domain Antibody (sdab) Inhibits Vascular Endothelial Growth Factor (VEGF) Production Via Intracellular Targeting of Signal Transducer and Activator of Transcription (STAT3).


2016 American Society of Clinical Oncology, Chicago, IL :

  • A Novel Single Domain Antibody (sdAb) SBT-100 Targets Intracellular STAT3 to Significantly Inhibit Growth and Causes Regression of Human Triple Negative Breast Cancer (TNBC) Cells.

  • A Novel Single Domain Antibody (sdAb) SBT-100 Targeting Intracellular STAT3 Inhibits All Major Subtypes of Human Breast Cancer.